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Abstract 
Ascididemin and Meridine are two marine compounds with pyridoacridine skeletons known to exhibit 
interesting antitumour activities. These molecules have been reported to behave like DNA intercalators. In this 
study, dialysis competition assay and mass spectrometry experiments were used to determine the affinity of 
ascididemin and meridine for DNA structures among duplexes, triplexes, quadruplexes and single-strands. Our 
data confirm that ascididemin and meridine interact with DNA but also recognize triplex and quadruplex 
structures. These molecules exhibit a significant preference for quadruplexes over duplexes or single-strands. 
Meridine is a stronger quadruplex ligand and therefore a stronger telomerase inhibitor than ascididemin (IC50=ll 
and >80 µM, respectively in a standard TRAP assay). 
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1. Introduction 
Researchers have long been investigating natural compounds as new anticancer drugs. In this way, different 
original metabolites with interesting cytotoxic properties have been reported from marine source. Several 
marine-derived metabolites have reached clinical trials as antitumour agents. Among marine alkaloids, the 
pyridoacridines seem to be the largest group, with most of the compounds being isolated from sponges and 
runicates (for a review, see [1]). In 1991, Schmitz et al. [2] described the isolation and structure of meridine (Fig. 
1A, left) from the ascidian Amphicarpa meridiana. Ascididemin (Fig. 1A, right) was isolated in 1988 by 
Kobayashi et al. [3] from a tunicate Didemnum  sp. Ascididemin and meridine differ by the attachment of the 
benzene ring, the position of a nitrogen atom and a hydroxyl  substituent in meridine. Different mechanisms of 
action for these polycyclic aromatic compounds have been proposed. Ascididemin is a conventional Topo II 
poison, but it is unlikely that topoisomerases are the main cellular targets of these molecules. Ascididemin is also 
capable of reductive DNA cleavage mediated by reactive oxygen species [4]. The binding mode of these 
derivatives to double-stranded DNA has been studied. Ascididemin intercalates between base pairs with a 
preference for GC-rich sequences [5]. 
Besides duplexes, DNA is prone to structural polymorphism and a number of alternative DNA structures have 
been described to date [6,7]. DNA conformation may differ from a regular double-helix and may involve the 
association of more than two strands, leading to the formation of triplexes and quadruplexes. Alternative DNA 
structures offer significant differences in terms of electrostatics, shape and rigidity compared to single- or 
double-stranded DNA. Therefore, specific recognition of unusual DNA structures such as triplexes and 
quadruplexes by small molecules such as pyridoacridines should be possible. 
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Fig. 1. (A) Formula of ascididemin (left), meridine (right) and RHPS4 (center) [27,54,66,67]. (B) A G-quartet 
(left) and a schematic drawing of an intramolecular antiparallel G-quadruplexes involving 3 quartets. 
 
G-quadruplexes are a family of secondary DNA structures formed in the presence of monovalent cations that 
consist of four-stranded structures stabilised by G-quartets (Fig. 1B) [8,9]. There is a renewed interest for G-
quadruplex structures due to their putative biological regulatory function. Telomeres protect chromosomal ends 
from fusion events and provide a mean for complete replication of the chromosome. Telomere repeats are added 
by a specialized enzyme, telomerase, which is overex-pressed in most tumour cells. In contrast, normal 
fibroblasts exert a very low level of telomerase previously thought to lack telomerase activity [10]. The                  
3'-terminal region of the G-rich strand of human telomeres is single-stranded and may adopt a G-quadruplex 
conformation [11,12]. This structure has been shown to directly inhibit telomerase elongation in vitro [13]. 
Therefore, ligands that selectively bind to G-quadruplex structures may interfere with telomere structure and 
telomere elongation and replication of cancer cells [14,15]. Several reviews concerning telomerase  inhibitors  in  
general or quadruplex-based telomerase inhibitors have been published in the last few years [16-23]. The recent 
discovery of natural compounds such as cryptolepine [24] and telomestatin [25,26] or of synthetic pentacyclic 
acridines (such as RHPS4)[27] that interact with G-quartets led us to test the binding of ascididemin and 
meridine to G-quadruplexes. 
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2. Materials and methods 
2.1.  Compounds 
Ascididemin and meridine were synthesized according to published procedures [28,29]. Stock solutions (1 mM 
for meridine, 2 mM for ascididemin) were prepared in DMSO and kept at -20 °C. Their formula are shown in 
Fig. 1A. 
2.2.  Oligonucleotides 
Oligodeoxynucleotide probes were synthesized by Eurogentec (Belgium) on the 1-µmol scale. Purity was 
checked by gel electrophoresis. All concentrations were expressed in strand molarity using a nearest-neighbour 
approximation for the absorption coefficients of the unfolded species [30]. All polynucleotides were ordered 
from Amersham-Pharmacia. F21MB is a doubly labelled 21-base-long oligomer that mimics the human 
telomeric guanine-rich strand with FAM at 5' end and DABCYL at 3' end respectively. It was synthesized and 
purified by Eurogentec (Belgium). 
2.3.  Dialysis experiments 
The initial dialysis protocol was defined by Ren and Chaires [31-33]. We have adapted this test to accommodate 
a different set of nucleic acid structures [24,34]. Briefly, a buffer consisting of 15 mM sodium cacodylate (pH 
6.5), 10 mM MgCl2, and 185 mM NaCl was used for all experiments. All structures used in these experiments 
were stable at room temperature under the chosen experimental conditions. 400 mL of the dialysate solution 
containing 1 µM ligand were used for each competition dialysis assay. A volume of 200 µL at 75 µM 
monomeric unit (nucleotide, base pair, base triplet or quartet) of each of the nucleic acids samples was pipeted 
into a separate Dialyzer unit (Pierce). A panel of 19 different nucleic acids structures were used. They have been 
described in details elsewhere [24]. All 19 dialysis units were then placed in the beaker containing the dialysate 
solution. The beaker was covered with Parafilm and wrapped in foil, and its contents were allowed to equilibrate 
with continuous stirring at room temperature (20-22 °C) overnight. At the end of the equilibration period, DNA 
samples were carefully removed to microfuge tubes, and treated with 1% SDS. The ligand concentration in each 
sample was determined by absorbance. 
2.4.  Fluorescence studies 
Fluorescence can be used to probe the secondary structure of oligodeoxynucleotides mimicking repeats of the 
guanine-rich strand of vertebrate telomeres, provided a FAM molecule (fluorescent tag) and a Dabcyl (quencher) 
are attached to the 5' and 3' ends of the oligonucleotide, respectively [35]. Fluorescence measurements with the 
F21MB oligonucleotide (0.2 µM) were initially performed on a Spex Fluoromax 3 instrument with 600 µL of 
solution in a 0.1 M lithium chloride, 10 mM sodium cacodylate pH 7.2 buffer [36]. In the experiments presented 
here, a real time PCR apparatus (MX3000P, Stratagene) was used, allowing the simultaneous recording of 
independent 96 samples. Each sample was studied in a 10 mM lithium cacodylate pH 7.2 buffer containing 50 
mM sodium chloride + 50 mM lithium chloride or 5 mM potassium chloride + 95 mM lithium chloride (buffer 
conditions labelled "Na+" and "K+", respectively). LiCl is added in order to approach physiological ionic strength 
without stabilising the quadruplex (lithium is a monocation which does not interact with G-quartets). The 
melting of the G-quadruplex was monitored in the presence and or in absence of the dye by measuring the 
fluorescence of fluorescein [36]. Several concentrations of each compound (1, 3, 5 or 10 µM) were tested, alone 
or in the presence of a double-stranded competitor (a self-complementary, 26 bp-long oligodeoxynucleotide 
"ds26", sequence 5' d-CAATCGGATCGAATTCGATCCGATTG 3'). This competitor, which is susceptible to 
"trap" a drug, will lower the stabilisation of the F21MB quadruplex. In the absence of a quadruplex-interacting 
drug, this competitor has no effect on the melting temperature of the F21MB quadruplex. All experiments were 
performed at least in duplicate, with a volume of 25 µL for each sample. Emission of fluorescein was normalized 
between 0 and 1, and the T1/2 was defined as the temperature for which the normalized emission is 0.5. 
2.5.  Mass spectrometry 
Oligodeoxynucleotides d-CGTAAATTTACG ("Dk33", M = 3644.45 Da), d-CGCGAATTCGCG ("Dk66", M = 
3646.44 Da), d-CGCGGGCCCGCG ("Dk100", M = 3678.40 Da), d-TGGGGT (M= 1863.26 Da), d-
GGGGTTTTGGGG (M = 3788.50 Da), d-(GGGTTA)3GGG (M = 6653.35 Da) were purchased from 
Eurogentec (Angleur, Belgium) and used without further purification. Duplex and quadruplex solutions were 
prepared according to previous reports [34]. Ammonium acetate was chosen as the electrolyte for its 
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compatibility with electrospray mass spectrometry. Experiments were performed on an LCQ mass spectrometer 
(Finnigan, San Jose, CA, USA) operated in the negative ion mode with a needle voltage of -2.6 kV. The 
experimental conditions were optimized to avoid denatura-tion of the duplex or quadruplex species. Full scan 
MS spectra were recorded in the m/z range [1000-2000], and 50 scans were summed for each spectrum. As the 
interaction of these compounds with DNA is relatively weak, spectra of 2:1 (10 µM drug, 5 µM structure) of all 
possible structure (duplex or quadruplex)+drug combinations were recorded. Methanol (15%) was added to the 
samples just before injection to obtain a stable electrospray signal. The rate of sample infusion into the mass 
spectrometer was 4 µL/min. As previously discussed, the relative intensities (obtained from a sum of 50 spectra) 
of the free and bound DNA in the mass spectra are assumed to be proportional to the relative abundances of 
these species in solution. The amount of bound ligand expressed in monomeric unit (base pair or quartet in the 
DNA target) is determined by dividing the total amount of bound ligand by the number of monomeric units in 
the DNA targets. 
2.6. TRAP assay 
The TRAP reaction was performed in a 20 mM Tris-HCl pH 8.3 buffer containing 63 mM KC1, 1.5 mM MgCl2, 
1 mM EGTA, 0.005% Tween 20, 0.1 mg/mL BSA, 50 µM dTTP, dGTP and dATP, 5 µM dCTP, and the 
oligonucleotides TS (5'-AATCCGTCGAGCAGAGTT-3') (0.4 µM), ACX (5'-
GCGCGGCTTACCCTTACCCTTACCCTAACC-3') (0.4 µM), NT (5'-ATCGCTTCTCGGCCTTTT-3') (0.4 
µM) and TSNT (5'-ATTCCGTCGAGCAGAGTTAAAAGG-CCGAGAAGCGAT-3') (20 amoles), 2 units of 
Taq polymerase, 0.02 mCi/mL dCTP32 (3000 Ci/mmol) and 200 ng of A431 CHAPS extracts. Various 
concentrations (0.5-100 µM) of ascididemin or meridine were tested, using freshly prepared aqueous dilutions of 
the compounds. As the stock solutions were prepared in DMSO, up to 5% DMSO was present (i.e., for 50 µM 
meridine or 100 µM ascididemin); we checked that 5% DMSO alone had no effect on telomerase activity (data 
not shown) After telomerase elongation for 15 min at 30 °C, 30 cycles of PCR were performed (94 °C 30 s, 50 
°C 30 s and 72 °C for 90 s). Telomerase extension products were then analysed on a denaturing 8% 
polyacrylamide, 7 M urea, 1 X Tris Borate EDTA (TBE) vertical gel. 
 
3. Results 
3.1. Equilibrium dialysis 
To evaluate the selectivity of ascididemin and meridine for different DNA structures, we performed a 
competitive dialysis experiment using 19 nucleic acids structures (described in Materials and methods) against a 
common ligand solution. More products accumulate in the dialysis tube containing the structural form with the 
highest ligand binding affinity [31,32]. It is possible to correlate the amount of the bound dye to a given structure 
with the affinity of the dye for that sample. As shown in Fig. 2A, ascididemin interacts preferentially with triplex 
and quad ruplex structures, whereas it shows a very weak affinity for single-strands and a moderate affinity for 
duplexes. Meridine (Fig. 2B) also interacts preferentially with triplex and quadruplex structures (especially with 
the human telomeric quadruplex, 22AG) as compared to single-strands and duplexes. The binding profile of the 
two compounds relative to higher-order DNA structures was quite unexpected and prompted us to confirm this 
interaction using different techniques. 
3.2. Mass spectrometry 
The ability of mass spectrometry to investigate drug-DNA interactions has been reviewed recently [37]. The 
binding stoichiometry, the relative binding affinities and the binding constants for DNA double-helices of 
various sequences may be determined and DNA complexes with intercalators and minor groove binders have 
been studied [38]. DNA quadruplex structures may also be investigated by electrospray mass spectrometry [39]. 
Fig. 3 presents the results obtained for two different quadruplexes, i.e., dTG4T, a tetramolecular quadruplex, and 
Telo, corresponding to 3.5 repeats of the human telomeric motif. These sequences are reminiscent of tetraplexes 
24G20 and 22AG used in the equilibrium dialysis assays, respectively. Formation of stable complexes between 
ascididemin (or meridine) and each quadruplex is demonstrated by the presence of peaks corresponding to 1:1 or 
2:1 drug-quadruplex complexes. The ratios of the intensities of the peaks of the complexes and the free 
quadruplex obtained with meridine were more important (compare panel B with A, and panel D with C) 
suggesting that meridine has a slightly higher affinity for quadruplexes than ascididemin, in agreement with 
equilibrium dialysis. 
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Fig. 2. Equilibrium dialysis. All measurements were performed in a 185 mM NaCl, 10 mM MgCl2, 15 mM Na-
cacodylate buffer (pH 6.5). The nucleic acid names are given on the left and all structures are described in 
Materials and methods. Triplexes are shown in green. Unusual parallel stranded duplexes, trinucleotide repeats 
and regular duplexes are shown in yellow, orange and blue, respectively. i-DNA are shown in light green and 
quadruplexes in red. Single-stranded polynucleotides are shown in black. (A) Ascididemin. (B) Meridine. 
 
The affinities of ascididemin and meridine for various DNA forms were then analysed by measuring their 
interactions with 12 base pairs duplexes with different GC content, [34]. Fig. 4 shows the quantitation of the 
results for 5 different structures (2 quadruplexes and 3 duplexes) for ascididemin (Fig. 4A) and meridine (Fig. 
4B). Overall, binding of meridine to all 5 DNA structures was stronger compared to ascididemin (compare X-
axis values on Fig. 4A and B). An apparent preference for quadruplexes over duplexes is also suggested by the 
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higher amount bound per motif. Again, a preference for the human telomeric sequence over the d[TGGGGT]4 
tetramolecular quadruplex is found. Within duplexes, binding was stronger to GC-rich over AT-rich sequences, 
as expected for DNA intercalators. 
3.3. Fluorescence melting experiments 
Dialysis and mass spectrometry experiments suggest that ascididemin and meridine interact with quadruplexes. 
Another method was implemented to confirm the interaction of these dyes with quadruplexes. We monitored by 
fluorescence the melting temperature of a fluorescent-tagged G-quadruplex (F21MB: 5'-Fluorescein-
GGGTTAGGGT-TAGGGTTAGGG-3'-DABCYL representing the human telomeric motif) in the presence of 
various concentrations (1-10 µM) of ascididemin (Fig. 5A, C, E) and meridine (Fig. 5B D F). In sodium, there is 
little stabilisation of the G-quadruplex with ascididemin (+1.2 °C at the highest concentration: 10 µM) and a 
weak stabilisation (∆T1/2 = +3.6 °C at 10 µM compound) with meridine. 
In the next series of experiments, sodium was replaced with potassium (panels C and D). Unsurprisingly, such a 
change led to a large increase of the melting temperature of the quadruplex alone as potassium is preferred over 
sodium by quadruplexes in general [8] and by the human intramolecular telomeric quadruplex in particular 
[35,40]. In order to stay in the same range of melting temperature for the quadruplex alone in sodium and in 
potassium, we chose to decrease the concentration of potassium to 5 mM and add 95 mM LiCl to keep a constant 
ionic strength. Under these experimental conditions, T1/2 was 54.9 °C (i.e., close to the T1/2 of 53.2 °C found in 
50 mM NaCl + 50 mM LiCl). More unexpected was the observation that the stabilisation induced by 
ascididemin and meridine is more pronounced in potassium than in sodium. At 10 µM, ascididemin and meridine 
stabilised the quadruplex by 5.7 and 11.4 °C, respectively. Lower concentrations (1, 3 or 5 µM) led to a less 
pronounced effect for both compounds. For example, ∆T1/2 at 1 µM were +0.9 and +1.4 °C for 1 µM ascididemin 
and meridine, respectively, and +2.9 and +7.1 °C for 5 µM ascididemin and meridine, respectively. In the 
concentration range tested (1-10 µM), meridine was always more potent than ascididemin towards quadruplex 
stabilisation. 
Fig. 3. Mass Spectrometry spectra. ESI-MS spectra of mixtures of 10 µM ascididemin (A, C) or meridine (B, D) 
with the parallel tetramolecular quadruplex d(TG4T)4 (panels A and B) or the human intramolecular quadruplex 
(panels C and D). Each structure was tested at a concentration of 5 µM with 10 µM ligand. Spectra were 
recorded using the LCQ instrument. 
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Fig. 4. Quantitation of ligand bound by Mass Spectrometry analysis. Concentration of bound ligand (per motif) 
deduced from the ESI-MS spectra of mixtures of 10 µM ascididemin (panel A) or meridine (panel B) with five 
different structures (5 µM): the human intramolecular quadruplex (GGGTTA)3GGG, the parallel tetramolecular 
quadruplex d[TG4T]4 and three self-complementary duplexes. 
 
Finally, the stabilisation observed in potassium at 10 µM compound was challenged by the addition of a double-
stranded competitor (Fig. 5E-F). Addition of a large excess of ds26, a self-complementary 26 base-long 
oligonucleotide of mixed base content had little effect on the ∆T1/2 obtained with meridine: the stabilisation was 
+8 °C in the presence of 30 µM ds26 (which corresponds to 390 µM in base pairs, or a 600-fold molar excess in 
base pairs over base quartets). This value is relatively close to the +11.4 °C stabilisation observed in the absence 
of a competitor, showing that meridine is weakly trapped by the presence of double-stranded DNA. For 
ascididemin, which is a weaker stabiliser (+5.7 °C at 10 µM), 30 µM ds26 led to a slightly more pronounced 
deleterious effect (∆T1/2 +2.0 °C). These results are in agreement with the equilibrium dialysis and mass 
spectrometry measurements which indicate a preferential interaction of ascididemin and meridine with the 
quadruplex-forming oligonucleotides. 
3.4. Telomerase inhibition 
Telomerase inhibition efficiency was measured by a TRAP assay. The non-folded, single-stranded form of the 
primer TS is required for optimal telomerase activity and quadruplex formation has been shown to directly 
inhibit telomerase elongation in vitro. A growing number of small molecules have been discovered to inhibit 
telomerase activity by inducing and/or stabilising G-quartet structure. Therefore, we performed here a TRAP 
assay with increasing concentrations (ranging 1 to 50 or 100 µM) of the compounds. Ascididemin inhibits 
telomerase with an IC50 of 87 µM (Fig. 6A). In agreement with its higher affinity for quadruplexes,  meridine  is  
clearly more  potent:   partial disappearance of the TRAP ladder is already found at 5 µM compound, and an IC50 
of 11 µM may be determined (Fig. 6B). The presence of an internal control (ITAS) discriminates inhibition of 
Taq polymerase during PCR amplification and telomerase elongation. A weak inhibition of the ITAS is detected 
with meridine at 50 µM (Fig. 6B, rightmost lane). Its IC50 against telomerase (11 µM) is significantly lower, 
demonstrating that telomerase inhibition is not the result of an artefactual PCR inhibition. Nevertheless, this IC50 
against telomerase is relatively modest when compared with the best G4-based telomerase inhibitors described 
and reflects a relatively weak interaction with G-quadruplexes. 
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Fig. 5. Stabilisation of human telomeric quadruplex by ascididemin and meridine. The thermal denaturation 
temperature of F21MB (followed by a variation of the fluorescence emission signal at 516nm)in 50 mMNaCl+50 
mM LiCl (panels A and B) or 5 mMKCl+95 mM LiCl (panels C-F) is recorded alone (solid line) or in the 
presence of 1, 3, 5 or 10 µM of ascididemin (left: panels A, C and E) or meridine (right: panel B, D and F). 
Inverted triangles: 1 µM drug; squares: 3 µM; crosses: 5 µM; diamonds: 10 µM. Stabilisation is more 
pronounced with meridine and when Na+ is replaced by K+. Panels E and F: the stabilisation induced by 10 µM 
ascididemin or meridine (diamonds) is partially maintained in the presence of 3 µM (dotted line); 10 µM 
(dashes) or 30 µM double-stranded competitor (large dashes) as compared to the control (solid line: no 
compound added). 
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Fig. 6. Telomerase inhibition by ascididemin and meridine in a TRAP assay. Increasing concentrations of 
compounds were added in the TRAP mixture in the presence of an internal control (ITAS). TRAP activity was 
determined with 200 ng of a CHAPS extract of A431 cell line. IC50 of 11 µM and 87 µM were determined for 




Marine organisms provide a valuable source for natural products and the biological activities of marine alkaloids 
have been studied widely. In this paper, we have used several methods to study the interaction of two alkaloids, 
ascididemin and meridine, with unusual DNA structures. These compounds bind to G-quadruplexes, as 
demonstrated by dialysis, mass spectrometry and fluorescence melting studies. However, their binding affinities 
are relatively modest (especially ascididemin) and these compounds also bind to triplexes. This is a recurrent 
observation for a number of quadruplex ligands: it has been relatively difficult to dissociate triplex and 
quadruplex affinity. Most of the quadruplex ligands exhibit similar and sometimes higher affinity for antiparallel 
triplexes [24,41]. Another potential problem, when in vivo applications are contemplated, comes from the fact 
that very few quadruplex ligands distinguish between the various classes of G-quadruplexes (intra- or inter-
molecular, parallel or antiparallel). Ascididemin and meridine are interesting exception to this rule, as they 
significantly prefer the human telomeric intramolecular quadruplex over the parallel one (see Fig. 2). 
Meridine stabilises the F21MB quadruplex by 5 °C at 1 µM in potassium whereas the best G4 ligands stabilise 
by 20 °C or more. These molecules cannot be considered as potent telomerase inhibitors (IC50=11-87 µM) as 
the best inhibitors described so far have an IC50 of 50 nM or lower. A surprising observation was the systematic 
higher stabilisation observed when sodium is replaced by potassium. This holds true both for ascididemin (+3.4 
instead of +1.2 °C) and meridine (+11.2 instead of+6.0 °C) at 10 µM, and is also valid at other dye 
concentrations. These data indicate that these dyes prefer to bind to the fluorescent F21MB oligonucleotide in 
potassium rather than in sodium. As recent data demonstrated that the crystal [12] and solution structure [42,43] 
of the human telomeric quadruplex in potassium may be different from the structure in sodium [11], one may 
propose that these two ligands have a preference for parallel over antiparallel quadruplexes. This preference for 
the K+ over the Na+ form seems to be a general rule for most of the ligands tested so far (L. Guittat and A. De 
Cian, unpublished observations). 
The number of G4 ligands has grown rapidly over a few years: a range of molecules has been shown to inhibit 
telomerase through binding to its substrate [14,26,27,36,44-59]. On the other hand, few natural products have 
been reported as G-quadruplex-mediated telomerase inhibitors, although one, telomestatin, is exceptionally 
potent with an IC50 of 5 nM against telomerase [25]. Even in view of the variability of the TRAP assay (in our 
hands, telomestatin has an IC50 of around 100 nM under our standard conditions), this molecule is, to our 
knowledge, one of the best small molecule telomerase inhibitor described so far. Telomestatin stabilises 
quadruplexes [26,60,61], interacts with the telomeric overhang [62] and is active against leukemia cells [63,64]. 
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These observations prompted us to search for other natural compounds that inhibit telomerase. General features 
of molecules that bind to G4 tetraplexes include a large flat aromatic surface, as ascididemin and meridine and 
are likely to adopt the terminal stacking mode. Despite their modest affinity for quadruplexes, ascididemin and 
meridine are promising as they bind specifically to higher order nucleic acid structures, as demonstrated by a 
variety of techniques (equilibrium dialysis, electrospray mass spectrometry, UV-vis spectroscopy and 
fluorescence melting assays). Due to technical constraints, buffer conditions may be different for each method. 
For example, NH4+ is the monocation of choice for ESI-MS. Despite these problems, all methods indicate that 
these two compounds bind to quadruplexes, although to a different extent. The most potent G4 stabiliser 
(meridine) is also the most potent telomerase inhibitor. This is in agreement with what was previously observed 
with dibenzophenanthro-lines [36] or triazines [65]. This should stimulate the interest in the modification of 
these marine alkaloids in order to provide ligands with higher affinity and inhibitory potential. In particular, the 
five aromatic cycles of meridine are arranged in a similar way as another synthetic pentacyclic acridine, 3,11-
difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4). In order to understand the better 
affinity of meridine as compared to ascididemin, the interaction energy of these compounds with the 
intramolecular antiparallel G-quadruplex structure (A(G3T2A)3G3 in Na+ [11] PDB code 143D) was calculated 
with the amber99 force field after a simulated annealing (SA) docking. Final energy minimization of the 
complex was performed using conjugate gradient (Polak-Riebiere) until a RMS gradient of 0.05 kcal/(A mol) 
was reached. The 1:1 end-stacked complexes have binding energies of -49 kcal/mol (ascididemin) and -53.1 
kcal/mol (meridine). Molecular modeling therefore confirms that meridine is a better G4-ligand than 
ascididemin. However, its calculated interaction energy remains modest compared to RHPS4 (-98.2 kcal/mol; 
data not shown). This positively-charged compound interacts with the human telomeric quadruplex, inhibits 
telomerase at submicromolar levels (IC50 of 0.33 µM), induces growth inhibitory effects in human tumour cell 
lines as well as cell cycle alterations, apoptosis and telomere dysfunction [27,66]. This compound may also 
interact with the parallel-stranded DNA quadruplex d[TTAGGGT]4 by stacking at the ends of the G-quadruplex 
[67]. The partial positive charge on position 13-N of the acridine ring of RHPS4 appears to act as a "pseudo" 
potassium ion and is positioned above the centre of the G-tetrad in the region of high negative charge density 
[67]. This charge, which is absent in meridine, could explain, at least in part, the large difference in affinity and 
telomerase inhibition found between meridine and RHPS4 (IC50 = 11 and 0.33 µM, respectively). Although 
meridine is currently inferior to the reference natural compound telo-mestatin (both in terms of quadruplex 
stabilisation and telomerase inhibition), efforts will now be aimed at synthesizing meridine analogs bearing one 
positive charge or more in order to increase affinity for quadruplexes. 
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